Jeff Knipstein

Company: Servier

Job title: Medical Director

Seminars:

Highlighting the Success of Vorasidenib for IDH-mutant Glioma: Development History and Current Approaches 12:30 pm

Presenting the history of vorasidenib’s clinical development and its success in slowing tumor progression in patients with IDH-mutant low grade gliomas Incorporating translational data to inform subsequent clinical trials for patients with recurrent IDH-mutant gliomas Developing vorasidenib for additional high-risk patients with IDH-mutant gliomasRead more

day: Conference Day 2